Table 1.
Demographics and Tumor Features of the Cohort
| 1G EGFR-TKI (n=100) | 2G EGFR-TKI (n=50) | 3G EGFR-TKI (n=50) | p value | |
|---|---|---|---|---|
| Age | 0.912 | |||
| <55 | 43(43%) | 28(56%) | 30(60%) | |
| ≥55 | 57(57%) | 22(44%) | 20(40%) | |
| Sex | 0.642 | |||
| Female | 56(56%) | 29(58%) | 32(64%) | |
| Male | 44(44%) | 21(42%) | 18(36%) | |
| KPS | 0.408 | |||
| >80 | 69(69%) | 33(66%) | 29(58%) | |
| ≤80 | 31(31%) | 17(34%) | 21(42%) | |
| Smoking index | 0.687 | |||
| Yes | 22(22%) | 10(20%) | 8(16%) | |
| No | 78(78%) | 40(80%) | 42(84%) | |
| Tumor stage | 0.633 | |||
| III | 13(13%) | 9(18%) | 6(12%) | |
| IV | 87(87%) | 41(82%) | 44(88%) | |
| Type of mutation | ||||
| 19del | 52(52%) | 16(32%) | 16(32%) | 0.016 |
| L858R | 40(40%) | 24(48%) | 13(26%) | 0.071 |
| Treatment line of target drugs | ||||
| First line | 88(88%) | 40(80%) | 36(72%) | 0.051 |
| Second line | 12(12%) | 10(20%) | 13(26%) | 0.090 |
| Third line | 0(0%) | 0(0%) | 1(2%) | 0.221 |
| Dose fractionation | 0.811 | |||
| SBRT | 14(14%) | 9(18%) | 8(16%) | |
| CFRT | 86(86%) | 41(82%) | 42(84%) | |
Abbreviations: 1G EGFR-TKI, first-generation epidermal growth factor receptor tyrosine kinase inhibitor; 2G EGFR-TKI, second-generation epidermal growth factor receptor tyrosine kinase inhibitor; 3G EGFR-TKI, third-generation epidermal growth factor receptor tyrosine kinase inhibitor; CFRT, conventionally fractionated radiation therapy; KPS, Karnofsky performance score; SBRT, stereotactic body radiation therapy.